Lundbeck to Buy Abide Therapeutics For $250M, Make SD Lab a US Hub

Danish pharma firm Lundbeck has agreed to acquire Abide Therapeutics for $250 million upfront. The La Jolla-CA-based company, spun out of research from The Scripps Research Institute (TSRI), is developing drugs to treat diseases of the central nervous system, among them Tourette syndrome. Its drugs block enzymes known as serine hydrolases, which play a role [?]